#JPM22 - Dealmaking in 2022: What's Big Pharma looking for and what is it willing to pay?
Okay, well, thanks everybody for coming out today. We had a ton of registrations for this panel discussion about dealmaking in 2022. I think that every year is a big year when it comes to dealmaking, M&A, and business development deals. And we’re certainly seeing a lot of interest this year, particularly after a very interesting 2021 — set the stage for a lot of people looking at where they’re at in terms of strategy, and how they position their company going into the new year.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.